GKCAS 2022 Annual Meeting
Didactic lectures given by speakers in the therapeutic areas of SCID, Mast Cell Activation, WHIM Syndrome, Eosinophilic Myocarditis and much more.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 3.25 contact hours.
Primary care physicians
Allied healthcare providers
At the conclusion of this activity learners should be able to:
- Identify when a biologic agent is indicated for asthma
- Select the most appropriate biologic for individual patients.
- Able to diagnose AERD
- Identify the best management option for individual AERD patients
- Recognize non-IgE-mediated food reactions and how to manage these disorders.
All identified conflicts of interest have been mitigated.
The individuals listed below disclose the following financial relationships:
Researcher: Blueprints Medicine- PI for two drug investigation studies (BLU-285 and BLU-263) which are tyrosine kinase inhibitors used to treat Mastocytosis
Researcher: NIH- PI for COVID Vaccine study
Advisor: Immune Deficiency Foundation
The following have no relevant financial relationships to disclose:
- 3.25 AMA PRA Category 1 Credit™
- 3.25 Attendance
- 3.25 CBRN